(Q79644417)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18932258%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

title

A phase 1 trial of 2 dose schedules of ABT-510, an antiangiogenic, thrombospondin-1-mimetic peptide, in patients with advanced cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18932258%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

main subject

phase I clinical trial

1 reference

inferred from title

angiogenesis inhibitor

1 reference

Michael S Gordon

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18932258%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

David Mendelson

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18932258%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

Robert Carr

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18932258%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

Raymond A Knight

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18932258%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

Rod A Humerickhouse

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18932258%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

Maria Iannone

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18932258%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

Alison T Stopeck

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18932258%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

publication date

1 December 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18932258%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18932258%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

volume

113

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18932258%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18932258%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

page(s)

3420-3429

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18932258%20AND%20SRC:MED&resulttype=core&format=json

Angiogenesis and tumor metastasis

24 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23953

7 January 2021

Reciprocal paracrine interactions between tumour cells and endothelial cells: the 'angiogenesis progression' hypothesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23953

7 January 2021

Halting angiogenesis suppresses carcinoma cell invasion

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23953

7 January 2021

VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23953

7 January 2021

Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23953

7 January 2021

Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23953

7 January 2021

CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23953

7 January 2021

Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23953

7 January 2021

A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23953

7 January 2021

Thrombospondin-1 is a major activator of TGF-beta1 in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23953

7 January 2021

Thrombospondin 1 expression in transformed endothelial cells restores a normal phenotype and suppresses their tumorigenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23953

7 January 2021

Tumor suppression in human skin carcinoma cells by chromosome 15 transfer or thrombospondin-1 overexpression through halted tumor vascularization

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23953

7 January 2021

A human fibrosarcoma inhibits systemic angiogenesis and the growth of experimental metastases via thrombospondin-1.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23953

7 January 2021

Three distinct D-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23953

7 January 2021

Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23953

7 January 2021

Phase I study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with 5-fluorouracil and leucovorin: a safe combination.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23953

7 January 2021

Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23953

7 January 2021

Expanding the clinical development of bevacizumab

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23953

7 January 2021

A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23953

7 January 2021

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23953

7 January 2021

High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23953

7 January 2021

Chemotherapy and the tumor microenvironment: the contribution of circulating endothelial cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23953

7 January 2021

Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23953

7 January 2021

Detection of circulating endothelial cells and endothelial progenitor cells by flow cytometry

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23953

7 January 2021

Molecular and cellular biomarkers for angiogenesis in clinical oncology

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23953

7 January 2021

Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23953

7 January 2021

Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23953

7 January 2021

Identifiers

DOI

10.1002/CNCR.23953

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18932258%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

1 reference